Corcept Therapeutics’ (CORT) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Corcept Therapeutics (NASDAQ:CORT) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $165.00 target price on the biotechnology company’s stock.

Other equities analysts have also issued reports about the company. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target on the stock. in a research note on Monday, July 27th. Truist Financial assumed coverage on shares of Corcept Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $164.00 target price on the stock. Piper Sandler reissued an “overweight” rating and set a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, UBS Group set a $135.00 price target on shares of Corcept Therapeutics in a report on Thursday, May 28th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $138.17.

Corcept Therapeutics Price Performance

CORT opened at $110.29 on Friday. Corcept Therapeutics has a twelve month low of $28.66 and a twelve month high of $126.38. The company has a fifty day moving average of $108.56 and a 200-day moving average of $75.48. The stock has a market cap of $11.92 billion, a PE ratio of 262.60 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.34. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The business had revenue of $256.15 million for the quarter, compared to analyst estimates of $221.15 million. During the same quarter in the previous year, the business earned $0.29 earnings per share. Corcept Therapeutics’s revenue for the quarter was up 31.7% on a year-over-year basis. Sell-side analysts anticipate that Corcept Therapeutics will post 1.86 EPS for the current fiscal year.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 25,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $114.43, for a total transaction of $2,860,750.00. Following the transaction, the insider owned 9,755 shares in the company, valued at approximately $1,116,264.65. This represents a 71.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joseph Lyon sold 10,000 shares of the firm’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $113.49, for a total transaction of $1,134,900.00. Following the completion of the transaction, the insider directly owned 5,683 shares in the company, valued at $644,963.67. This trade represents a 63.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 446,415 shares of company stock worth $50,674,595 in the last ninety days. 20.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Corcept Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CORT. State of Wyoming grew its stake in Corcept Therapeutics by 29.5% in the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 186 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Corcept Therapeutics during the second quarter worth about $27,000. Campbell Newman Asset Management Inc. raised its position in Corcept Therapeutics by 1.9% in the first quarter. Campbell Newman Asset Management Inc. now owns 17,251 shares of the biotechnology company’s stock worth $695,000 after acquiring an additional 320 shares during the period. Gould Capital LLC raised its position in Corcept Therapeutics by 66.7% in the first quarter. Gould Capital LLC now owns 1,000 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 400 shares during the period. Finally, Arizona State Retirement System boosted its stake in Corcept Therapeutics by 1.6% in the second quarter. Arizona State Retirement System now owns 26,417 shares of the biotechnology company’s stock valued at $2,297,000 after acquiring an additional 414 shares during the last quarter. 93.61% of the stock is owned by institutional investors.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended marketing authorization for Lifyorli (relacorilant) combined with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The recommendation moves Corcept closer to a potential European launch, expanding the commercial opportunity for its oncology pipeline, although final approval by the European Commission is still required. Corcept receives CHMP recommendation
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $165 price target, implying substantial upside from recent trading levels. The bullish view reflects optimism about Lifyorli’s regulatory progress and Corcept’s growth potential.
• Positive Sentiment: Zacks Research raised several longer-term EPS forecasts, including its FY2027 estimate to $2.05 from $1.91 and FY2028 estimate to $4.31 from $4.07. These revisions suggest analysts see improving earnings potential as new products contribute to revenue.
• Neutral Sentiment: Reports highlighted Corcept among companies benefiting from favorable European drug recommendations, reinforcing the visibility of the Lifyorli regulatory milestone. EU drug recommendations
• Negative Sentiment: James Wilson, a Corcept director, sold 10,000 shares for approximately $1.11 million, while another insider previously sold 10,000 shares. Wilson still retains more than 1.06 million shares, limiting the significance of the transaction, but insider selling can weigh on investor sentiment.
• Negative Sentiment: Zacks’ FY2026 EPS estimate of $1.39 is below the broader full-year consensus of $2.02, indicating some concern about near-term earnings expectations despite stronger later-year forecasts.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.

Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.